EP4378527A3 — Transmucosal therapeutic system containing agomelatine
Assigned to LTS Lohmann Therapie Systeme AG · Expires 2024-09-11 · 2y expired
What this patent protects
The present invention relates to transmucosal therapeutic systems for the transmucosal administration of agomelatine comprising a mucoadhesive layer structure comprising a therapeutically effective amount of agomelatine, such agomelatine transmucosal therapeutic systems for use i…
USPTO Abstract
The present invention relates to transmucosal therapeutic systems for the transmucosal administration of agomelatine comprising a mucoadhesive layer structure comprising a therapeutically effective amount of agomelatine, such agomelatine transmucosal therapeutic systems for use in a method of treatment, a method of treatment comprising applying such agomelatine transmucosal therapeutic systems, and processes of manufacture of such transmucosal therapeutic systems.
Drugs covered by this patent
- Subutex (Buprenorphine Hydrochloride) · Indivior
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.